Metformin, a biguanide antidiabetic agent that can be administered either alone or in combination with sulfonylureas, has been extensively used in Europe and Canada. The mechanism of action of metformin and other biguanides is not completely understood, but recent in vitro and in vivo studies suggest that metformin may act in part by both increasing the binding of insulin to its receptor and potentiating insulin action. Metformin, because of its chemical structure, does not interact with the liver and has a short half-life. Consequently, lactic acidosis, which is a rare complication of metformin, has not been associated with the proper use of this drug. In addition to its antidiabetic actions, metformin causes weight loss in obese diabetic patients and may be useful in managing associated lipid disorders.
Skip Nav Destination
Article navigation
Review|
January 01 1987
Role of metformin in treatment of diabetes mellitus
In Special Collection:
Review Articles
Riccardo Vigneri, MD;
Riccardo Vigneri, MD
Cattedra di Endocrinologia e Patologia Costituzionale, University of Catania
Ospedale Garibaldi, Catania, Italy
Search for other works by this author on:
Ira D Goldfine, MD
Ira D Goldfine, MD
Cell Biology Laboratory, Mount Zion Hospital and Medical Center, and the Department of Medicine and Physiology, University of California
San Francisco, California
Search for other works by this author on:
Address correspondence and reprint requests to Prof. Riccardo Vigneri, Endocrinologia Università di Catania, Ospedale Garibaldi, 95123 Catania, Italy.
Citation
Riccardo Vigneri, Ira D Goldfine; Role of metformin in treatment of diabetes mellitus. Diabetes Care 1 January 1987; 10 (1): 118–122. https://doi.org/10.2337/diacare.10.1.118
Download citation file: